|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
US20070203058A1
(en)
*
|
2003-09-19 |
2007-08-30 |
Novo Nordisk A/S |
Novel Glp-1 Derivatives
|
|
US20060046962A1
(en)
|
2004-08-25 |
2006-03-02 |
Aegis Therapeutics Llc |
Absorption enhancers for drug administration
|
|
US8268791B2
(en)
*
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
|
US20140162965A1
(en)
|
2004-08-25 |
2014-06-12 |
Aegis Therapeutics, Inc. |
Compositions for oral drug administration
|
|
US9895444B2
(en)
|
2004-08-25 |
2018-02-20 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
AU2006224537A1
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
ES2426445T3
(es)
|
2006-04-07 |
2013-10-23 |
Merrion Research Iii Limited |
Forma de dosificación oral sólida que contiene un potenciador
|
|
US8173594B2
(en)
*
|
2006-06-23 |
2012-05-08 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US20090326193A1
(en)
*
|
2006-06-23 |
2009-12-31 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US8226949B2
(en)
|
2006-06-23 |
2012-07-24 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US8084022B2
(en)
*
|
2006-06-23 |
2011-12-27 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US7425542B2
(en)
*
|
2006-06-23 |
2008-09-16 |
Aegis Therapeutics, Inc. |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US7998927B2
(en)
*
|
2006-06-23 |
2011-08-16 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
|
US20100261637A1
(en)
*
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
DK2597103T3
(en)
|
2007-11-16 |
2017-02-13 |
Novo Nordisk As |
Stable pharmaceutical compositions comprising liraglutide and degludec
|
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
PT2254906T
(pt)
|
2008-03-18 |
2017-01-03 |
Novo Nordisk As |
Análogos de insulina acilados, estabilizados contra proteases
|
|
CA2756690C
(en)
|
2008-03-28 |
2016-08-16 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
|
KR20110007614A
(ko)
|
2008-05-07 |
2011-01-24 |
메리온 리서치 Ⅲ 리미티드 |
ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
|
|
AU2009279090A1
(en)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk Health Care Ag |
Conjugated proteins with prolonged in vivo efficacy
|
|
CN106317164A
(zh)
|
2008-09-12 |
2017-01-11 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
|
US8440631B2
(en)
|
2008-12-22 |
2013-05-14 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
|
JP5816097B2
(ja)
|
2009-01-22 |
2015-11-18 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
|
AU2010207721B2
(en)
|
2009-01-23 |
2015-03-26 |
Novo Nordisk A/S |
FGF21 derivatives with albumin binder A-B-C-D-E- and their use
|
|
EP2440235A1
(en)
*
|
2009-06-11 |
2012-04-18 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
DK2454282T3
(en)
|
2009-07-13 |
2015-05-04 |
Zealand Pharma As |
acetylated glucagonanaloger
|
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
|
JP6006118B2
(ja)
*
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
AU2011208620B2
(en)
|
2010-01-22 |
2015-04-16 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
|
CN103002918B
(zh)
|
2010-01-22 |
2016-05-04 |
诺沃—诺迪斯克保健股份有限公司 |
体内功效延长的生长激素
|
|
EP2539364A1
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
|
CN102918055B
(zh)
*
|
2010-03-26 |
2017-03-29 |
诺沃—诺迪斯克有限公司 |
新的胰高血糖素类似物
|
|
WO2011120033A1
(en)
|
2010-03-26 |
2011-09-29 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor xa inhibitors for oral administration
|
|
AU2011247824B2
(en)
*
|
2010-04-27 |
2014-02-13 |
Betta Pharmaceuticals Co., Ltd |
Glucagon-like peptide-1 analogue and use thereof
|
|
CN102186881B
(zh)
*
|
2010-04-27 |
2015-04-08 |
贝达药业股份有限公司 |
胰高血糖素样肽-1衍生物及其应用
|
|
JP5819946B2
(ja)
*
|
2010-05-17 |
2015-11-24 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
新規のグルカゴン様ペプチド類似体、組成物、および使用方法
|
|
WO2012016419A1
(zh)
*
|
2010-08-06 |
2012-02-09 |
浙江贝达药业有限公司 |
Glp-1衍生物及其应用
|
|
JP6231386B2
(ja)
|
2010-11-09 |
2017-11-15 |
ノヴォ ノルディスク アー／エス |
リンカーを有する二重アシル化されたｇｌｐ−１誘導体
|
|
RS60321B1
(sr)
*
|
2010-12-16 |
2020-07-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
|
|
AU2012204213A1
(en)
|
2011-01-07 |
2013-06-13 |
Merrion Research Iii Limited |
Pharmaceutical compositions of iron for oral administration
|
|
WO2012098187A1
(en)
|
2011-01-19 |
2012-07-26 |
Novo Nordisk A/S |
Glp-1 compositions
|
|
WO2012098188A1
(en)
|
2011-01-19 |
2012-07-26 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
|
EP2691108A1
(en)
*
|
2011-03-28 |
2014-02-05 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
KR101496136B1
(ko)
*
|
2011-03-30 |
2015-02-26 |
베타 파머수티컬 컴퍼니 리미티드 |
글루카곤 유사 펩타이드-1 유사체 및 이의 용도
|
|
ES2712945T3
(es)
*
|
2011-04-12 |
2019-05-16 |
Novo Nordisk As |
Derivados de GLP-1 doblemente acilados
|
|
RU2602601C2
(ru)
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
|
DK3415139T3
(da)
|
2011-06-14 |
2022-06-20 |
Neurelis Inc |
Administration af benzodiazepin
|
|
AU2012286048A1
(en)
|
2011-07-18 |
2014-02-20 |
Arts Biologics A/S |
Long acting luteinizing hormone (LH) compound
|
|
CN104039822A
(zh)
|
2011-09-06 |
2014-09-10 |
诺沃—诺迪斯克有限公司 |
Glp-1衍生物
|
|
AR088161A1
(es)
|
2011-09-23 |
2014-05-14 |
Novo Nordisk As |
Analogos de glucagon
|
|
CN110041399B
(zh)
|
2011-12-29 |
2023-12-12 |
诺沃—诺迪斯克有限公司 |
包含非成蛋白质性的氨基酸的二肽
|
|
DK2814844T3
(da)
|
2012-02-15 |
2017-11-13 |
Novo Nordisk As |
Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)
|
|
ES2690786T3
(es)
|
2012-02-15 |
2018-11-22 |
Novo Nordisk A/S |
Anticuerpos que se unen a la proteína 1 de reconocimiento de peptidoglicano
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
|
LT2827885T
(lt)
|
2012-03-22 |
2018-10-10 |
Novo Nordisk A/S |
Glp-1 peptidų kompozicijos ir jų gavimas
|
|
CN111494323B
(zh)
|
2012-03-22 |
2023-03-28 |
诺和诺德股份有限公司 |
包含递送剂的组合物及其制备
|
|
PT2827885T
(pt)
*
|
2012-03-22 |
2018-11-05 |
Novo Nordisk As |
Composições de péptidos glp-1 e sua preparação
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
CN104519902B
(zh)
|
2012-05-08 |
2017-10-27 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
|
EP2846824B1
(en)
*
|
2012-05-08 |
2017-04-05 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
CN112142855A
(zh)
|
2012-05-18 |
2020-12-29 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
|
HRP20200889T1
(hr)
|
2012-07-01 |
2020-09-04 |
Novo Nordisk A/S |
Upotreba dugodjelujućih peptida glp-1
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
EP2908844A1
(en)
*
|
2012-10-17 |
2015-08-26 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
|
EP2981282B1
(en)
|
2013-04-05 |
2020-11-04 |
Novo Nordisk Health Care AG |
Growth hormone compound formulation
|
|
SI2986313T1
(sl)
*
|
2013-04-18 |
2019-09-30 |
Novo Nordisk A/S |
Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
|
|
RU2671406C2
(ru)
|
2013-05-02 |
2018-10-31 |
Ново Нордиск А/С |
Пероральная дозированная форма соединений глюкагоноподобного пептида-1
|
|
JP6475233B2
(ja)
*
|
2013-06-20 |
2019-02-27 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
AU2014286234A1
(en)
|
2013-07-04 |
2015-12-17 |
Novo Nordisk A/S |
Derivatives of GLP-1 like peptides, and uses thereof
|
|
US10266577B2
(en)
|
2013-08-15 |
2019-04-23 |
Novo Nordisk A/S |
GLP-1 derivatives, and uses thereof
|
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
|
WO2015038938A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
CA2939763A1
(en)
|
2014-02-18 |
2015-08-27 |
Novo Nordisk A/S |
Stable glucagon analogues and use for treatment of hypoglycaemia
|
|
JP6768515B2
(ja)
|
2014-04-07 |
2020-10-14 |
ノヴォ ノルディスク アー／エス |
二重アシル化ｇｌｐ−１化合物
|
|
TWI668010B
(zh)
|
2014-05-07 |
2019-08-11 |
丹麥商諾佛 儂迪克股份有限公司 |
使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
|
|
CN106536547A
(zh)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
用于医疗用途的glp‑1/胰高血糖素受体共激动剂
|
|
CA2955253C
(en)
|
2014-07-17 |
2023-03-07 |
Novo Nordisk A/S |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
|
|
ES2685987T3
(es)
|
2014-09-05 |
2018-10-15 |
University Of Copenhagen |
Análogos de péptidos gip
|
|
GR20140100479A
(el)
*
|
2014-09-23 |
2016-05-05 |
Novetide, Ltd., |
Συνθεση λιραγλουτιδης
|
|
ES2630106T3
(es)
|
2014-10-07 |
2017-08-18 |
Cyprumed Gmbh |
Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
US11572398B2
(en)
|
2014-11-27 |
2023-02-07 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
US10392428B2
(en)
|
2014-12-17 |
2019-08-27 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
MX377044B
(es)
|
2014-12-23 |
2025-03-07 |
Novo Nordisk As |
Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
|
|
JP2018505173A
(ja)
*
|
2015-01-29 |
2018-02-22 |
ノヴォ ノルディスク アー／エス |
錠剤コアと即時放出コーティングとを含む経口ｇｌｐ−１投与用の医薬組成物
|
|
ES2975708T3
(es)
|
2015-01-29 |
2024-07-12 |
Novo Nordisk As |
Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
|
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|
|
AU2016280873A1
(en)
*
|
2015-06-16 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Long acting liraglutide compositions
|
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药（苏州）股份有限公司 |
艾塞那肽修饰物及其用途
|
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
|
CN106554408A
(zh)
*
|
2015-09-30 |
2017-04-05 |
天津药物研究院有限公司 |
长效胰高血糖素样肽-1类似物二聚体及其应用
|
|
CN108135962A
(zh)
|
2015-10-07 |
2018-06-08 |
塞浦路迈德有限责任公司 |
用于口服递送肽类药物的药物制剂
|
|
CN106928343A
(zh)
*
|
2015-12-30 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
索玛鲁肽的制备方法
|
|
US10946074B2
(en)
|
2016-03-03 |
2021-03-16 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
CN107266557B
(zh)
*
|
2016-04-06 |
2020-04-07 |
天津药物研究院有限公司 |
一种聚乙二醇修饰的胰高血糖素样肽-1类似物
|
|
DK3448416T3
(da)
*
|
2016-04-28 |
2022-10-03 |
Novo Nordisk As |
Semaglutid ved kardiovaskulære tilstande
|
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
|
WO2018078112A1
(en)
|
2016-10-27 |
2018-05-03 |
Aarhus Universitet |
Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
|
|
EP3534962B1
(en)
|
2016-11-07 |
2020-08-19 |
Novo Nordisk A/S |
Dchbs-active esters of peg compounds and their use
|
|
TWI700091B
(zh)
|
2016-12-16 |
2020-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
含胰島素醫藥組成物
|
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
|
JP2020510028A
(ja)
*
|
2017-03-08 |
2020-04-02 |
インターシア セラピューティクス，インコーポレイティド |
薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
|
|
EP3630806B1
(en)
|
2017-05-31 |
2024-01-10 |
The University of Copenhagen |
Long-acting gip peptide analogues
|
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
|
CN109248323B
(zh)
*
|
2017-07-14 |
2023-09-08 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
|
TW201918494A
(zh)
*
|
2017-07-19 |
2019-05-16 |
丹麥商諾佛 儂迪克股份有限公司 |
雙功能性化合物
|
|
EP4360651A3
(en)
*
|
2017-08-24 |
2024-07-17 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
WO2019048660A1
(en)
|
2017-09-10 |
2019-03-14 |
Novo Nordisk A/S |
MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
|
|
KR102612576B1
(ko)
|
2017-09-29 |
2023-12-12 |
한미약품 주식회사 |
링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
|
|
KR20200069316A
(ko)
|
2017-10-12 |
2020-06-16 |
노보 노르디스크 에이/에스 |
의료 요법에서의 세마글루타이드
|
|
CN107881187A
(zh)
*
|
2017-11-20 |
2018-04-06 |
珠海联邦制药股份有限公司 |
将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
|
|
US11186608B2
(en)
|
2017-12-21 |
2021-11-30 |
Bachem Holding Ag |
Solid phase synthesis of acylated peptides
|
|
HUE063787T2
(hu)
|
2018-02-02 |
2024-01-28 |
Novo Nordisk As |
Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
|
|
JP6941224B2
(ja)
|
2018-02-06 |
2021-09-29 |
イージス セラピューティクス，エルエルシー |
疾患の処置のための鼻腔内エピネフリン製剤及び方法
|
|
CN110294800B
(zh)
*
|
2018-03-22 |
2022-03-04 |
齐鲁制药有限公司 |
一种索玛鲁肽的制备方法
|
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
|
WO2019193576A1
(en)
|
2018-04-05 |
2019-10-10 |
Sun Pharmaceutical Industries Limited |
Novel glp-1 analogues
|
|
WO2019193204A1
(en)
|
2018-04-06 |
2019-10-10 |
Cyprumed Gmbh |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
|
WO2019200594A1
(zh)
*
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
|
CN110386974B
(zh)
*
|
2018-04-19 |
2022-12-09 |
杭州先为达生物科技有限公司 |
Glp-1衍生物及其治疗用途
|
|
MA52483A
(fr)
|
2018-05-04 |
2021-03-10 |
Novo Nordisk As |
Dérivés de gip et leurs utilisations
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
HRP20230929T1
(hr)
*
|
2018-10-26 |
2023-11-24 |
Novo Nordisk A/S |
Stabilni pripravci semaglutida i njihova upotreba
|
|
CN109180801B
(zh)
*
|
2018-11-01 |
2021-08-13 |
汉肽生物医药集团有限公司 |
一种合成索玛鲁肽的方法
|
|
US12187773B2
(en)
|
2018-12-03 |
2025-01-07 |
Antag Therapeutics Aps |
Modified GIP peptide analogues
|
|
WO2020127476A1
(en)
|
2018-12-19 |
2020-06-25 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
|
EP3897582B1
(en)
|
2018-12-21 |
2024-09-11 |
Novo Nordisk A/S |
Process of spray drying of glp-1 peptide
|
|
WO2020152304A1
(en)
|
2019-01-24 |
2020-07-30 |
Novo Nordisk A/S |
Roller compactor and method of dry granulation using a roller compactor
|
|
CN119455003A
(zh)
|
2019-02-12 |
2025-02-18 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
MA55008A
(fr)
|
2019-02-20 |
2021-12-29 |
Novo Nordisk As |
Aminoacyl-arnt synthétases et leurs utilisations
|
|
EP3930757A1
(en)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
WO2020190757A1
(en)
|
2019-03-15 |
2020-09-24 |
Novetide Ltd. |
Improved processes for the preparation of semaglutide
|
|
MY210034A
(en)
|
2019-03-15 |
2025-08-22 |
Novo Nordisk As |
Process for spray drying a glp-1 peptide
|
|
CN111748019A
(zh)
*
|
2019-03-29 |
2020-10-09 |
深圳翰宇药业股份有限公司 |
一种多肽衍生化合物的合成方法
|
|
WO2020201280A1
(en)
|
2019-04-01 |
2020-10-08 |
Novo Nordisk A/S |
Antibodies directed against liraglutide and use thereof
|
|
KR20210149747A
(ko)
*
|
2019-04-11 |
2021-12-09 |
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 |
다중-수용체 작용제 및 그의 의학 용도
|
|
CN111909256A
(zh)
*
|
2019-05-10 |
2020-11-10 |
宁波鲲鹏生物科技有限公司 |
多肽衍生物及其制备方法
|
|
EA202193102A1
(ru)
*
|
2019-05-21 |
2022-02-17 |
Медиммун Лимитед |
Инъекционные совместные составы на основе циклодекстрина, содержащие ингибиторы sglt2 и инкретиновые пептиды
|
|
CN114340655A
(zh)
|
2019-09-02 |
2022-04-12 |
诺和诺德股份有限公司 |
生产包含glp-1肽的片剂的方法
|
|
BR112022004697A2
(pt)
*
|
2019-09-16 |
2022-06-14 |
Biomarin Pharm Inc |
Variantes de cnp e conjugados das mesmas
|
|
CN110590934B
(zh)
*
|
2019-09-25 |
2020-12-08 |
北京乐普医药科技有限公司 |
一种glp-1化合物
|
|
RS65780B1
(sr)
|
2019-11-06 |
2024-08-30 |
Novo Nordisk As |
Semaglutid u lečenju alchajmerove demencije
|
|
EP3819308A1
(en)
|
2019-11-07 |
2021-05-12 |
Fresenius Kabi iPSUM S.r.l. |
Process for the manufacture of derivatized amino acids
|
|
WO2021089752A1
(en)
|
2019-11-07 |
2021-05-14 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
|
WO2021123228A1
(en)
|
2019-12-18 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
|
JP2023510218A
(ja)
*
|
2019-12-30 |
2023-03-13 |
ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド |
長時間作用型ｇｌｐ－１化合物
|
|
WO2021136223A1
(en)
|
2019-12-31 |
2021-07-08 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
CN115322794B
(zh)
|
2020-01-11 |
2025-09-19 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
SMT202400344T1
(it)
|
2020-02-07 |
2024-11-15 |
Gasherbrum Bio Inc |
Agonisti di glp-1 eterociclici
|
|
KR102375262B1
(ko)
|
2020-02-14 |
2022-03-16 |
주식회사 지투지바이오 |
Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
|
|
TWI878456B
(zh)
|
2020-02-18 |
2025-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
|
CN111253475B
(zh)
*
|
2020-02-18 |
2021-03-09 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Glp-1激动多肽化合物及其盐与合成方法及用途
|
|
EP4132960A2
(en)
|
2020-04-10 |
2023-02-15 |
Fresenius Kabi Oncology Limited |
An improved process for the preparation of semaglutide side chain
|
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
|
CN115461044B
(zh)
|
2020-04-29 |
2025-06-10 |
诺和诺德股份有限公司 |
包含glp-1激动剂和组氨酸的固体组合物
|
|
AR122579A1
(es)
*
|
2020-06-12 |
2022-09-21 |
Lilly Co Eli |
Proceso para preparar un agonista dual glp-1 / glucagón
|
|
MX2023000403A
(es)
|
2020-07-22 |
2023-02-02 |
Novo Nordisk As |
Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
|
|
TW202220973A
(zh)
|
2020-08-06 |
2022-06-01 |
美商迦舒布魯姆生物有限公司 |
雜環glp-1促效劑
|
|
CA3190606A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
|
JP2023541827A
(ja)
|
2020-09-07 |
2023-10-04 |
サイプルメド ゲーエムベーハー |
Ｇｌｐ－１受容体アゴニストの改善された医薬製剤
|
|
KR20230083294A
(ko)
|
2020-09-30 |
2023-06-09 |
베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 |
폴리펩타이드 접합체 및 사용 방법
|
|
MX2023004672A
(es)
|
2020-11-06 |
2023-07-20 |
Novo Nordisk As |
Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
|
|
TWI850611B
(zh)
|
2020-12-18 |
2024-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
US20240209056A1
(en)
|
2021-03-25 |
2024-06-27 |
Brightgene Bio-Medical Technology Co., Ltd. |
Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
|
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
TW202304500A
(zh)
|
2021-04-21 |
2023-02-01 |
瑞士商諾華公司 |
升糖素樣肽化合物
|
|
JP2024522196A
(ja)
|
2021-06-09 |
2024-06-11 |
ザ スクリプス リサーチ インスティテュート |
長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
|
|
AU2022289247A1
(en)
|
2021-06-10 |
2023-12-21 |
Antag Therapeutics Aps |
Treatment of obesity and obesity-related disorders
|
|
AU2022298186B2
(en)
|
2021-06-23 |
2024-10-03 |
Peptron, Inc. |
Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
|
|
WO2022268214A1
(zh)
|
2021-06-25 |
2022-12-29 |
甘李药业股份有限公司 |
Pcsk9抑制剂和glp-1受体激动剂的药物组合
|
|
US20250276043A1
(en)
*
|
2021-06-25 |
2025-09-04 |
Gan & Lee Pharmaceuticals Co., Ltd. |
Pharmaceutical Composition Containing GLP-1 Compound
|
|
WO2023285347A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
|
JP2024527613A
(ja)
|
2021-07-14 |
2024-07-25 |
ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド |
代謝性障害のための融合ポリペプチド
|
|
PE20241302A1
(es)
|
2021-07-15 |
2024-06-24 |
Novo Nordisk As |
Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
|
|
CN116410297A
(zh)
*
|
2021-07-19 |
2023-07-11 |
内蒙古博睿精创科技有限公司 |
长效glp-1多肽类似物及其制备方法和应用
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
MX2024002863A
(es)
|
2021-09-08 |
2024-03-21 |
Shionogi & Co |
Medicina para la prevencion y tratamiento de enfermedades vinculadas a la actividad antiobesidad.
|
|
AU2022386166A1
(en)
|
2021-11-10 |
2024-06-20 |
I2O Therapeutics, Inc. |
Ionic liquid compositions
|
|
TWI876242B
(zh)
|
2021-12-13 |
2025-03-11 |
丹麥商諾佛 儂迪克股份有限公司 |
包括環糊精的醫藥調配物
|
|
AU2022413318A1
(en)
|
2021-12-13 |
2024-05-16 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
EP4490155A1
(en)
|
2022-03-09 |
2025-01-15 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
JP2025510741A
(ja)
|
2022-03-21 |
2025-04-15 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環式ｇｌｐ－１アゴニスト
|
|
WO2023187067A1
(en)
|
2022-03-30 |
2023-10-05 |
Novo Nordisk A/S |
Formulation method
|
|
JP2025512832A
(ja)
|
2022-03-30 |
2025-04-22 |
ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド |
ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
|
|
CN119255988A
(zh)
|
2022-04-14 |
2025-01-03 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
JP2025517672A
(ja)
|
2022-05-10 |
2025-06-10 |
ノヴォ ノルディスク アー／エス |
プロドラッグおよびその使用
|
|
IL316466A
(en)
|
2022-05-23 |
2024-12-01 |
Ascendis Pharma Growth Disorders As |
Liquid pharmaceutical formulations of cnp compounds
|
|
IL318154A
(en)
|
2022-07-05 |
2025-03-01 |
G2Gbio Inc |
A composition containing a microsphere for sustained release of semaglutide pharmaceutical salt and methods for making the same
|
|
TW202421654A
(zh)
|
2022-09-28 |
2024-06-01 |
丹麥商西蘭製藥公司 |
治療肥胖之方法
|
|
WO2024079043A1
(en)
|
2022-10-10 |
2024-04-18 |
Bachem Holding Ag |
Method of manufacturing a peptide with a lysine derivative
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202421645A
(zh)
|
2022-11-25 |
2024-06-01 |
丹麥商諾佛 儂迪克股份有限公司 |
如ｇｌｐ—１之肽治療劑的口服投與
|
|
WO2024128882A1
(ko)
|
2022-12-16 |
2024-06-20 |
주식회사 펩트론 |
Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
|
|
CN116159027A
(zh)
*
|
2022-12-29 |
2023-05-26 |
江苏诺泰澳赛诺生物制药股份有限公司 |
一种司美格鲁肽冻干药物组合物及其制备方法
|
|
CN121001710A
(zh)
|
2022-12-30 |
2025-11-21 |
阿尔吉法玛公司 |
提高口服多肽治疗剂的全身生物利用度的组合物和方法
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
CN120731085A
(zh)
*
|
2023-03-02 |
2025-09-30 |
甘李药业股份有限公司 |
一种glp-1化合物的医药用途
|
|
IL323019A
(en)
|
2023-03-06 |
2025-10-01 |
Ascendis Pharma As |
Drug compounds with an albumin-binding moiety
|
|
EP4676535A1
(en)
|
2023-03-06 |
2026-01-14 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
AU2024232757A1
(en)
|
2023-03-06 |
2025-08-21 |
Ascendis Pharma A/S |
Drug compounds comprising albumin-binding moieties
|
|
KR20250162619A
(ko)
|
2023-03-20 |
2025-11-18 |
아센디스 파마 그로우쓰 디스오더스 에이/에스 |
연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
|
|
AR132255A1
(es)
|
2023-03-30 |
2025-06-11 |
Novo Nordisk As |
Compuestos de fusión y usos de estos
|
|
WO2024234320A1
(zh)
*
|
2023-05-17 |
2024-11-21 |
南京知和医药科技有限公司 |
一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
|
|
WO2024252366A1
(en)
|
2023-06-09 |
2024-12-12 |
Sun Pharmaceutical Industries Limited |
Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
|
|
KR20240176455A
(ko)
|
2023-06-15 |
2024-12-24 |
노보 노르디스크 에이/에스 |
시클로덱스트린을 포함하는 약학적 제형
|
|
WO2025069009A1
(en)
|
2023-09-29 |
2025-04-03 |
Graviton Bioscience Bv |
Rock2 inhibitors in the treatment of obesity
|
|
WO2025078040A1
(en)
|
2023-10-09 |
2025-04-17 |
Bachem Holding Ag |
Lysine salt and method of manufacturing a lysine derivative
|
|
WO2025077751A1
(zh)
*
|
2023-10-09 |
2025-04-17 |
甘李药业股份有限公司 |
Glp-1肽组合物及其用途
|
|
TW202521100A
(zh)
|
2023-11-17 |
2025-06-01 |
美商雅沛尼美德公司（德拉瓦州公司） |
使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
|
|
WO2025114501A1
(en)
|
2023-11-30 |
2025-06-05 |
Novo Nordisk A/S |
Tri-agonists of the glp-1, gip, and amylin receptors
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
US20250326814A1
(en)
|
2024-02-06 |
2025-10-23 |
Opko Biologics Ltd. |
Modified oxyntomodulin and methods of use thereof
|
|
EP4684801A1
(en)
|
2024-07-23 |
2026-01-28 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
WO2025172606A1
(en)
|
2024-02-16 |
2025-08-21 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
WO2025172605A1
(en)
|
2024-02-16 |
2025-08-21 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4684802A1
(en)
|
2024-07-23 |
2026-01-28 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4603080A1
(en)
|
2024-02-16 |
2025-08-20 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4603079A1
(en)
|
2024-02-16 |
2025-08-20 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
GB202403746D0
(en)
|
2024-03-15 |
2024-05-01 |
New Roger Randal Charles |
Formulations demonstrating an oral depot effect
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
WO2026008836A1
(en)
|
2024-07-05 |
2026-01-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|